Close Menu

NEW YORK – 23andMe has received 510(k) clearance from the US Food and Drug Administration for its CYP2C19 Drug Metabolism Report, which informs customers whether their genotypes may influence their ability to respond to clopidogrel and citalopram without the need for confirmatory testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.